Gibson, Dunn & Crutcher LLP
Client SatisfactionTackling both transactions and disputes in the life sciences sector, Gibson, Dunn & Crutcher LLP is sought out by clients engaged in Hatch-Waxman and product liability litigation, in addition to those both seeking financing or seeing through M&A. Taking the lead on corporate and transactional matters is Ryan Murr, who counsels pharmaceutical, biotech and diagnostics companies on business combinations and securities transactions out of San Francisco, while New York-based Jane Love spearheads the practice’s efforts on the IP front, where she represents clients in litigation concerning biologics and small molecule therapies.
Legal 500 Editorial commentary
Key clients
- Guardant Health
- Gilead Sciences
- Dental Monitoring SAS
- Merck & Co., Inc.
- Cullgen Inc.
- GE Healthcare
- CTI BioPharma Inc.
- Elliott Investment Management L.P.
- Heska Corporation
- Tenet Healthcare Corporation
- Royalty Pharma
- Lincoln International
- MoonLake Immunotherapeutics
- BioCryst Pharmaceuticals, Inc.
- Mirum Pharmaceuticals, Inc.
- Sutro Biopharma, Inc.
- Dianthus Therapeutics, Inc.
- 89bio, Ltd.
- Apogee Therapeutics, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Cogent BioSciences, Inc.
- Ultragenyx Pharmaceutical Inc.
- Spyre Therapeutics, Inc.
- Neurogene
- Spectrum Pharmaceuticals
- Concentra Biosciences
Work highlights
- Advised Elliott Investment Management on the $7.1bn acquisition by a private investment consortium of Syneos Health.
- Advised Cullgen on a $1.9bn strategic collaboration and option agreement to advance innovative targeted protein degraders with Astellas Pharma.
- Advised Merck on its $1.35bn acquisition of Imago BioSciences, Inc.
Practice head
The lawyer(s) leading their teams.
Ryan Murr, Jane Love